Abstract：
Type 2 diabetes represents a growing challenge for global public health. Its prevalence is increasing worldwide, and, like obesity, it affects progressively younger populations compared to the past, with potentially greater impact on chronic complications. Dual glucagon like peptide 1 (GLP1) and glucose-dependent insulinotropic peptide (GIP) receptor agonists are among the new pharmacological strategies recently developed to address this challenge. Tirzepatide, characterized by its ability to selectively bind and activate receptors for the intestinal hormones GIP and GLP-1, has been tested in numerous clinical studies and is already currently authorized in several countries for the treatment of type 2 diabetes and obesity. In this context, the aim of the present document is to summarize, in the form of a narrative literature review, the currently available data on the main mechanisms of action of GIP/GLP-1 co-agonists and the clinical effects of tirzepatide evaluated in various clinical trials.
摘要：
2型糖尿病对全球公共卫生构成了日益严峻的挑战。它在世界范围内的患病率正在增加，and,比如肥胖，与过去相比，它影响到越来越年轻的人群，对慢性并发症的潜在影响更大。双重胰高血糖素样肽1（GLP1）和葡萄糖依赖性促胰岛素肽（GIP）受体激动剂是最近开发的应对这一挑战的新药理学策略之一。Tirzepatide,其特征在于其选择性结合和激活肠激素GIP和GLP-1的受体的能力,已经在许多临床研究中进行了测试,并且目前已经在多个国家被授权用于治疗2型糖尿病和肥胖症。在这种情况下，本文件的目的是总结，以叙事文献综述的形式，关于GIP/GLP-1共激动剂的主要作用机制和替利西帕肽的临床效果的现有数据在各种临床试验中进行了评估.
